Our Pricing

Understanding Mounjaro Patches: What's Available in the UK

Published: 10 September 2026

Many patients ask about mounjaro patches as a potential alternative to injections for weight management. Currently, Mounjaro (tirzepatide) is only licensed and available as a subcutaneous injection in the UK, with no transdermal patch formulation approved by the MHRA. Understanding the current delivery methods and ongoing research into alternative formulations helps patients make informed decisions about their weight loss treatment.

Are Mounjaro Patches Available in the UK?

Mounjaro patches do not currently exist as an approved medication in the United Kingdom. The only licensed form of tirzepatide available is the subcutaneous injection administered via the KwikPen device [1]. The MHRA has not approved any transdermal patch formulation of Mounjaro, and no pharmaceutical company has submitted such a product for regulatory review in the UK market.

The confusion around mounjaro patches often stems from general interest in needle-free alternatives for chronic medications. While transdermal patches exist for various medications including hormone replacement therapy and nicotine cessation, the molecular structure and dosing requirements of tirzepatide make patch delivery technically challenging [2]. Current research focuses on optimising the existing injection formulation rather than developing alternative delivery systems.

Why Mounjaro Patches Don't Exist: Scientific Challenges

The absence of mounjaro patches relates to fundamental pharmacological barriers. Tirzepatide is a large peptide molecule with a molecular weight exceeding 4,800 Daltons, making it too large to penetrate the skin barrier effectively [3]. Transdermal patches work best with small, lipophilic molecules that can diffuse through the stratum corneum, whereas tirzepatide requires precise subcutaneous delivery to achieve therapeutic blood levels.

Additionally, the weekly dosing schedule of Mounjaro necessitates sustained, controlled release of precise microgram quantities. Current patch technology cannot reliably deliver peptide medications of this size whilst maintaining stability and bioavailability over a seven-day period [4]. The injection method ensures 100% bioavailability and predictable pharmacokinetics, which is why it remains the gold standard for GLP-1 and GIP receptor agonists.

Molecular Size and Skin Permeability

The skin's protective barrier prevents molecules larger than 500 Daltons from penetrating effectively without enhancement technologies. Mounjaro's active ingredient exceeds this threshold nearly tenfold, requiring subcutaneous administration to bypass the epidermis entirely. Even with penetration enhancers, maintaining therapeutic concentrations through a patch would require an impractically large surface area and potentially cause skin irritation.

Current Mounjaro Delivery Method: Injection Pens

Instead of mounjaro patches, patients receive treatment through pre-filled KwikPen injectors designed for once-weekly subcutaneous administration. These pens contain single doses ranging from 2.5mg to 15mg, delivered via a fine 32-gauge needle into the abdomen, thigh, or upper arm [1]. The injection process takes seconds, and most patients report minimal discomfort due to the ultra-thin needle design.

The pen device features automatic needle insertion and dose delivery, eliminating the need for manual injection technique. Clinical trials from the SURPASS programme demonstrated that over 90% of patients successfully self-administered injections after initial training [5]. The subcutaneous route ensures reliable absorption and maintains stable tirzepatide levels throughout the week, supporting consistent appetite suppression and glycaemic control.

Injection Site Rotation and Comfort

Proper injection technique involves rotating between different sites to prevent lipodystrophy and maintain absorption consistency. Patients typically alternate between the abdomen and thighs weekly, avoiding areas within 5cm of the navel or previous injection sites. Most individuals find the injection process becomes routine within the first month, with discomfort ratings averaging below 2 on a 10-point scale in patient surveys.

Alternative Delivery Methods to Mounjaro Patches

While mounjaro patches remain unavailable, pharmaceutical research explores several needle-free delivery technologies for peptide medications. Oral formulations represent the most advanced alternative, with semaglutide (Wegovy® Oral Tablets) now available in the UK as the first GLP-1 receptor agonist pill [6]. This formulation uses absorption enhancers to facilitate uptake through the gastric mucosa, though it requires specific administration conditions including fasting.

Other experimental approaches include microneedle patches, which use microscopic projections to penetrate only the outer skin layers, and inhalable formulations currently in early-stage trials. However, none of these technologies have been successfully applied to tirzepatide, and regulatory approval would require extensive clinical trials demonstrating equivalent efficacy and safety to the injection formulation. For the foreseeable future, subcutaneous injection remains the only clinically proven method for Mounjaro administration.

Mounjaro Patches vs Injection: Efficacy Comparison

Since mounjaro patches do not exist, no comparative efficacy data is available. However, theoretical comparisons with other transdermal medications suggest that patch formulations typically achieve 40-60% of the bioavailability of injected equivalents [2]. This reduced absorption would necessitate significantly higher doses to match the weight loss results observed in SURPASS trials, where patients achieved average reductions of 15-20% body weight on maximum doses [5].

The injection method's superior bioavailability ensures that the full therapeutic dose reaches systemic circulation, maximising the dual GLP-1 and GIP receptor activation that distinguishes Mounjaro from single-agonist therapies. Any future patch technology would need to demonstrate non-inferior weight loss outcomes and similar safety profiles before the MHRA would consider approval. Current evidence strongly supports injection as the optimal delivery route for tirzepatide therapy.

Patient Preference Studies

Survey data from weight management programmes indicates that 70% of patients initially prefer oral or transdermal options over injections. However, after three months of injection therapy, preference shifts significantly, with 65% of continuing patients reporting satisfaction with the pen device and citing superior results as the primary factor. This suggests that whilst mounjaro patches might appeal theoretically, the proven efficacy of injections outweighs delivery method concerns for most individuals.

Getting Mounjaro Treatment Without Patches in the UK

Patients seeking mounjaro patches can access the approved injection formulation through Cured Pharmacy from £124.99, following a free online clinical assessment. Our UK-registered prescribers evaluate eligibility based on BMI criteria, medical history, and contraindications during a consultation taking under three minutes [1]. All prescriptions comply with MHRA guidelines and NICE recommendations for tirzepatide use in weight management.

Treatment begins with the 2.5mg starter dose, administered weekly for four weeks before escalating to 5mg. Dose titration continues monthly up to a maximum of 15mg, guided by individual response and tolerability. Patients receive comprehensive injection training materials and ongoing support from our clinical team led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073). Discreet packaging ensures privacy, and UK-licensed medicines guarantee authenticity and quality standards.

Scientific References

1. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Medicines.org.uk. [accessed 10 September 2026]
2. Prausnitz, M. R., & Langer, R. (2008). Transdermal drug delivery. Nature Biotechnology, 26(11), 1261-1268. [accessed 10 September 2026]
3. Coskun, T., et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism, 18, 3-14. [accessed 10 September 2026]
4. Fosgerau, K., & Hoffmann, T. (2015). Peptide therapeutics: current status and future directions. Drug Discovery Today, 20(1), 122-128. [accessed 10 September 2026]
5. Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 10 September 2026]
6. Buckley, S. T., et al. (2018). Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Science Translational Medicine, 10(467), eaar7047. [accessed 10 September 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 10 September 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 10 September 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 10 September 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.